References
- Maloney, D.G., Smith, B. and Appelbaum, F.R. (1996) "The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines (abs)", Blood 88, 1537.
- Reff, ME., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Neuimann, R.A., Hana, N. and Anderson, R.A. (1994) "Depletion of B cells in vivo by a chimeric mouse monoclonal antibody to CD20", Blood, 435–445.
- Grillo-Lopez, A.J., White, C.A., Varns, C.A., Bodkin, D., Schnilder, R.J., Neidhart, J.A., Janokinamon, N., Foon, K.A., Liles, TM., Dallaire, B.K., Wey, K., Royston, 1., Davis, T. and Levy, R. (1999) "Overview of the clinical development of rituximab first monoclonal antibody approved for the treatment of lymphoma", Semin. Oncol. 26, 66–73.
- Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdaville, R., Diehl, V. and Reyes, F. (1998) "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study", Blood 92, 1927–1932.
- Leget, G.A. and Czuczman, M.S. (1998) "Use of rituximab, the new FDA-approved antibody", Curr Opin. Oncol. 10, 548–551.
- Byrd, LC., Waselenko, J.K., Maneatis, T.J., Murphy, T., Ward, F.T., Monahan, B.F. and Sipe, M.A. (1999) "Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion related side effects and rapid blood tumor clearance", J. Clin. Oncol. 17, 791–795.
- Berentsen, S., Tionnfjord, G.E., Brudevold, R., Gjersten, B.T., Langholm, R., Lokkevik, E., Sorbo, J.H. and Ulvestad, E. (2001) "Favourable response to therapy with anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease", Br J. Haemarol. 115, 79–83.
- Ahrens, N., Kingreen, D., Seltsan, A. and Salama, A. (2001) —Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (Rituuximab)", Br J. Haematol. 114, 244–245. Ghazal, H. (2002) "Successfull treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia", Blood 99, 1092–1094.
- Abdel-Raheen, M.M., Potti, A. and Kobrinsky, N. (2001) "Severe Evans' syndrome secondary to interleukein-2 threapy: treatment with chimeric monoclonal anti-CD20 antibody", Ann. Hemarol. 80, 543–545.
- McLaughin, R, Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S. and Williams, M.E. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program", J. Clin. Oncol. 16, 2825–2833.
- Zaja, F., Russo, D., Fuga, G., Michelutti, T., Speretto, A., Fanin, R. and Baccarani, M. (2001) "Rituximab in a case of cold agglutinin disease", Br J. Haematol. 114, 232–233.
- Perrotta, S., Locatelli, F., La Mana, A„ Cennamo, L., Stefano, P.D. and Nobili, B. (2002) "Anti-CD20 monoclonal antibody (Rituxi-mab) for life threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus", Br J. Haemmol, 116, 463–467.
- Hagberg, H. and Lindholn, L. (2001) "Rituximab, a chimeric anti-CD20 monoclonal antibody in the treatment of hairy cell leukaemia", Br J. Haematol, 115, 609–611.
- Perotta, A., Sunneberg, D.A., Scott, J., Ratanatharapron, V., Hook, C., Attas, L., Dawson, D. and Kunkel, L.A. (2001) "Rituximab in the treatment of chronic idiopathic thrombocytopenic purpura (abs)", Blood 94\(Suppl. 1), 49.